BioWorld

March 24, 2004

Structural GenomiX Signs First FAST Platform Partner: Serono

In a deal worth up to $68 million, Structural GenomiX agreed to use its FAST drug discovery technology with Serono SA to develop small-molecule therapeutics. (BioWorld Today) Read More

Shire Could Pay AnorMed Up To $31M For Fosrenol Global Patents

After Chemo-Induced Menopause, Fertility In Breast Cancer Patient Restored By Cryopreservation

Bioenvision Stock Placement Gets $12.8M For Clofarabine

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...